Benefits of Deep Brain Stimulation Persist in Parkinson Disease
Reductions in time spent with dyskinesia, time spent in the off state, and in dopaminergic drugs sustained for more than 15 years.
Parkinson Disease
NeuroSphere Virtual Clinic Allows for Remote Neuromodulation Therapy Management
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.
Certain Prostate Drugs Tied to Risk for Parkinson Disease
Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin
Gocovri Approved to Treat Off Episodes in Parkinson Disease
Results from both studies showed there was a significant increase in “on” time without troublesome dyskinesia, and a significant decrease in “off” time.
Kynmobi Now Available to Treat Off Episodes in Parkinson Disease
Apomorphine is believed to treat off episodes associated with PD through stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain.
Plasma Caffeine Concentration Lower in Parkinson Disease
Results similar for caffeine metabolites and non-xanthine marker for coffee consumption in plasma.
New Drug Application for Apomorphine Infusion Pump Submitted for Review
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study.
Ongentys Now Available as Add-On Treatment for Parkinson Disease
Ongentys is an oral, selective and reversible inhibitor of catechol-O-methyltransferase.
App Approval Provides Flexibility for Patients Treated With Abbott’s Neuromodulation Devices
The FDA has approved an iOS-compatible app designed to work in tandem with Abbott’s neuromodulation technologies. The Company hopes the app will eliminate the need for patients to carry a separate programmer device and improve remote care.
Gocovri sNDA Under Review for Off Episodes in Parkinson Disease
The FDA has accepted for review the supplemental New Drug Application (sNDA) for Gocovri® (amantadine extended-release; Adamas Pharmaceuticals) for the treatment of off episodes in Parkinson disease (PD) patients receiving levodopa-based therapy.
